Composition for improving intestinal infectious injury as well as preparation method and application thereof

Abstract

The invention relates to the technical field of food processing, in particular to a composition for improving intestinal infectious injury and a preparation method and application thereof. The composition for improving the intestinal infectious injury is prepared from the following components in parts by weight: 30 to 50 parts of lactic acid bacteria, 20 to 50 parts of lactobacillus reuteri metagen and 50 to 120 parts of dietary fiber. According to the composition disclosed by the invention, the lactobacillus plantarum, the lactobacillus delbrueckii, the lactobacillus reuteri, the lactobacillus mucilaginosus, and the prebiotics are compounded and have a synergistic effect, so that the intestinal injury can be better and faster repaired.

Description

Technical Field

[0001] The invention relates to the technical field of food processing, and in particular to a composition for improving intestinal infectious damage, and a preparation method and application thereof. Background Art

[0002] At present, in terms of enteritis diseases, intestinal damage caused by bacterial enteritis is a common intestinal disease. Inflammatory bowel disease is mainly caused by bacterial infection of the intestine. Its symptoms are extremely complex and vary in severity. Mild cases will cause abdominal distension, abdominal pain, nausea and vomiting, affecting the absorption of nutrients. Severe cases will have complications such as intestinal necrosis and colon cancer. However, in clinical treatment of bacterial enteritis, most methods are based on antibiotics. Long-term and extensive use of antibiotics will not only increase the patient's drug resistance, but also lead to gastrointestinal flora imbalance and cause a variety of diseases.

[0003] Chinese patent CN115887625A discloses a composition for promoting intestinal repair and its preparation method. The composition contains arachidonic acid, lactoferrin, and vitamin D, and verifies the repair effects of arachidonic acid, lactoferrin, and vitamin D on intestinal epithelial cells, intestinal organoids, and mouse intestinal epithelial damage, and the composite powder of the three substances has the best effect in promoting intestinal repair. However, the lactoferrin and arachidonic acid mentioned in the composition are relatively expensive, and the processing technology is complicated, and the cost of application in production is relatively high.

[0004] Chinese patent CN108135948A discloses a composition for use in treating and / or preventing gastrointestinal conditions, the composition comprising at least one Lactobacillus strain, wherein the Lactobacillus strain is selected from the group consisting of a Lactobacillus salivarius strain, three Lactobacillus plantarum strains and a Lactobacillus brevis strain, wherein the Lactobacillus salivarius strain is Lactobacillus salivarius CW30 (LMG P-28887), wherein the Lactobacillus plantarum strain is Lactobacillus plantarum Y1An734 (LMG P-28886), Lactobacillus plantarum SH1313 (LMG P-28884), and Lactobacillus plantarum KS11 (LMG P-28885), and wherein the Lactobacillus brevis strain is Lactobacillus brevis SH111 (LMG P-28888). The composition is used to treat and / or prevent gastrointestinal diseases, and can effectively protect the intestinal tract from colonization by foreign pathogens and potentially harmful inherent microorganisms. However, the invention has not yet described in detail whether Lactobacillus plantarum has a therapeutic and / or preventive effect on related intestinal diseases with a higher degree of infection. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a natural, healthy, safe, effective, palatable composition that can improve intestinal infectious damage to replace clinical treatment methods such as drugs or surgery.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] The present application provides a composition for improving intestinal infectious damage, comprising the following components by weight: 30-50 parts of lactic acid bacteria, 20-50 parts of Lactobacillus reuteri postbiotics and 50-120 parts of dietary fiber.

[0008] In some embodiments of the present application, the lactic acid bacteria include Lactobacillus plantarum Ali.Plateau.LP.Ⅷ and Lactobacillus delbrueckii subsp.Lactis Dangxiong LBⅧ, wherein the preservation number of Lactobacillus plantarum Ali.Plateau.LP.Ⅷ is CCTCC No.M 2021340, and the preservation number of Lactobacillus delbrueckii subsp.Lactis Dangxiong LBⅧ is CCTCC No.M 2023396; preferably, the number of viable cells in the lactic acid bacteria is 2.0×10 9 -5.0×10 10 CFU / g.

[0009] In some embodiments of the present application, the Lactobacillus reuteri is Limosilactobacillus reuteri NAQU LR V, with the deposit number: CCTCC NO: M20221538.

[0010] In some embodiments of the present application, the composition for improving intestinal infectious damage comprises the following components by weight: 30-50 parts of lactic acid bacteria, 30-40 parts of Lactobacillus reuteri postbiotics, and 60-85 parts of dietary fiber;

[0011] Preferably, the composition comprises the following components in parts by weight: 40-50 parts of lactic acid bacteria, 30-40 parts of Lactobacillus reuteri postbiotics and 80-85 parts of dietary fiber.

[0012] In some embodiments of the present application, the dietary fiber includes one or more of fructo-oligosaccharides, inulin and xylo-oligosaccharides;

[0013] Preferably, the dietary fiber includes fructooligosaccharides, inulin and xylo-oligosaccharides;

[0014] More preferably, in parts by weight, the dietary fiber comprises 15-50 parts of inulin, 15-50 parts of fructo-oligosaccharides and 15-50 parts of xylo-oligosaccharides; preferably, the dietary fiber comprises 15-20 parts of inulin, 30-40 parts of fructo-oligosaccharides and 15-35 parts of xylo-oligosaccharides; more preferably, the dietary fiber comprises 15-20 parts of inulin, 35-40 parts of fructo-oligosaccharides and 20-35 parts of xylo-oligosaccharides.

[0015] In some embodiments of the present application, the composition further comprises fruit and vegetable powder;

[0016] Preferably, in parts by weight, the fruit and vegetable powder is 10 to 15 parts;

[0017] More preferably, the fruit and vegetable powder includes one or more of blueberry powder, strawberry powder, cranberry powder and carrot powder.

[0018] In some embodiments of the present application, the lactic acid bacteria powder is a lactic acid bacteria microcapsule powder, wherein the microcapsule powder comprises a core material and a wall material, the core material comprises lactic acid bacteria, and preferably the wall material comprises a gelling agent, a cross-linking agent and a laccase;

[0019] Preferably, the gelling agent comprises one or more of sodium alginate, arabinoxylan and arabinoxy-oligosaccharide, preferably sodium alginate, arabinoxylan and arabinoxy-oligosaccharide, more preferably, the weight ratio of sodium alginate, arabinoxylan and arabinoxy-oligosaccharide is 1-2:1-4:0.5-1, and further preferably, the addition amount of the laccase is 1-2nkat / mg arabinoxylan;

[0020] More preferably, the cross-linking agent comprises calcium chloride and / or calcium lactate.

[0021] In some embodiments of the present application, the Lactobacillus reuteri postbiotic is prepared by fermenting and inactivating Lactobacillus reuteri and then spray-drying it.

[0022] The present application also provides a method for preparing the above-mentioned composition, comprising stirring and mixing the raw materials;

[0023] Preferably, the dietary fiber and the fruit and vegetable powder are stirred and mixed, and then stirred and mixed with the lactic acid bacteria and the Lactobacillus reuteri postbiotics.

[0024] More preferably, the stirring speed is 3-7 r / min, and the preferred stirring time is 15-30 min.

[0025] In some embodiments of the present application, in the above preparation method, the lactic acid bacteria is lactic acid bacteria microcapsule powder, and the lactic acid bacteria microcapsule powder comprises the following steps:

[0026] (1) fermenting lactic acid bacteria to obtain bacterial sludge, and then preparing a heavy suspension;

[0027] (2) Adding a gelling agent, laccase and a cross-linking agent to the resuspended solution of step (1) to react, and then freeze-drying to obtain lactic acid bacteria microcapsule powder.

[0028] In some embodiments of the present application, in the above preparation method, the Lactobacillus reuteri postbiotic comprises the following steps:

[0029] (1) inoculating the activated Lactobacillus reuteri into a fermentation medium for fermentation;

[0030] (2) heating the fermentation liquid from step (1) to sterilize and inactivate it;

[0031] (3) homogenizing the fermentation liquid inactivated in step (2), and then spray drying to obtain Lactobacillus reuteri powder;

[0032] Preferably, the fermentation medium in step (1) comprises 140-160 parts by weight of skim milk powder, 20-40 parts by weight of glucose and 10-30 parts by weight of peptone; and / or,

[0033] Step (2) heating to 60-80°C for sterilization and / or

[0034] The air inlet temperature of the spray drying in step (3) is 130-160°C, and the air outlet temperature is 40-60°C.

[0035] The present application also provides the use of the above composition or the composition prepared by the above preparation method in the preparation of medicines, health products or foods for improving intestinal infectious damage.

[0036] The present application also provides a medicine, health product or food containing the above composition or the composition prepared by the above preparation method; preferably, the food is one of a compressed candy or a solid beverage.

[0037] In some embodiments of the present application, it further includes auxiliary materials; preferably, the auxiliary materials are selected from one or more of sucrose, mannitol, sorbitol, dextrin, magnesium stearate, lactose, microcrystalline cellulose, starch, white sugar, xylose and sucralose steviol glycoside.

[0038] Beneficial effects of the present invention:

[0039] The composition of the present invention is compounded with Lactobacillus plantarum, Lactobacillus delbrueckii and Lactobacillus mucilaginosus postbiotics and prebiotics to achieve synergistic effects and can repair intestinal damage better and faster.

[0040] Strain deposit information

[0041] The plant lactobacillus used in the present invention is plant lactobacillus (Lactobacillus plantarum) Ali. Plateau. LP. VIII, which was deposited in the China Center for Type Culture Collection (CCTCC) on January 13, 2022, with a deposit number of CCTCC NO: M 2022068, and a deposit address: Wuhan University, Wuhan, China, postal code: 430072; telephone: (027)-68754052. The strain has been recorded in the patent application with Chinese application number 202210895628.7 (publication number CN115838654 A).

[0042] The Lactobacillus delbrueckii subsp. Lactis Dangxiong LBⅧ used in the present invention was deposited in the China Center for Type Culture Collection (CCTCC) on March 23, 2023, with a deposit number of CCTCC NO: M 2023396, and a deposit address: Wuhan University, Wuhan, China, postal code: 430072; telephone: (027)-68754052. The strain has been recorded in the patent application with Chinese application number CN202310802241.7 (publication number CN116948884A).

[0043] The Lactobacillus reuteri NAQU LRV used in the present invention was deposited in the China Center for Type Culture Collection (CCTCC) on September 30, 2022, with a deposit number of CCTCC NO: M20221538, and a deposit address: Wuhan University, Wuhan, China, postal code: 430072; telephone: (027)-68754052. The strain has been recorded in the patent application with Chinese application number CN202410146983.3 (publication number CN118272251A). BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 The results of the experimental study on the repair of the small intestine of mice damaged by E. coli infection by the composition;

[0045] Figure 2 The results of the experimental study on the repair of the small intestine of mice damaged by Salmonella typhimurium infection with the composition;

[0046] Figure 3 The results of the experiment on the composition repairing the large intestine of mice damaged by E. coli infection;

[0047] Figure 4 The results of the experiment on the repair of the large intestine of mice damaged by Salmonella typhimurium infection by the composition;

[0048] Figure 5 The expression of Claudin-1 in small intestine tissue in the E. coli infection model;

[0049] Figure 6 The expression of Claudin-1 in the small intestine in the Salmonella typhimurium infection model;

[0050] Figure 7 The expression of Zo-1 in the mouse small intestine in the infection model. DETAILED DESCRIPTION

[0051] In order to make the purpose, technical scheme and technical effect of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention is described clearly and completely. The embodiments described below are part of the embodiments of the present invention, not all of them. In combination with the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0052] In recent years, the use of probiotics to improve intestinal health and prevent or treat intestinal diseases has received increasing attention. As a major category of probiotics, lactic acid bacteria are the most representative of their probiotic functions. A large number of studies have shown that lactic acid bacteria may be a promising method for treating bacterial enteritis. The macromolecules on the cell wall of lactic acid bacteria can prevent or inhibit the binding of pathogenic bacteria to the surface receptors of intestinal cells, and can also adhere to the gastrointestinal tract and colonize, regulate the intestinal microbiota, and restore the balance of the host's intestinal microecological environment, thereby playing a role in alleviating and treating bacterial enteritis.

[0053] In this application, postbiotics refer to preparations of inactivated microorganisms and / or their metabolites for food that are beneficial to the health of the host, excluding purified metabolites.

[0054] Related studies have shown that bioactive molecules such as proteins, lipids, short-chain fatty acids, vitamins, and bacteriocins in the metabolites of inactivated lactic acid bacteria have great potential in improving human health, such as antagonizing pathogens, preventing obesity, regulating immunity, and improving intestinal health. And from the perspective of practical application, since the probiotic properties of postbiotics do not depend on the activity of probiotics, they have higher stability and safety than live microorganisms.

[0055] Prebiotics are a part of food that is not easily digested. They have a positive impact on intestinal health by selectively activating the growth and activity of one or several bacteria in the human intestine. Common prebiotics such as xylooligosaccharides, fructo-oligosaccharides and isomalto-oligosaccharides are highly fermented and expanded by intestinal flora. The short-chain fatty acids produced in the colon can not only serve as nutrients for intestinal flora, but also regulate the pH value of the intestine, making it easier for probiotics to grow in the intestine. They are increasingly gaining attention in the treatment and prevention of intestinal diseases.

[0056] Therefore, the present invention provides a natural, healthy, safe, effective, palatable composition that can improve intestinal infectious damage to replace clinical drug or surgical treatment methods. The composition is compounded with postbiotics and prebiotics of Lactobacillus plantarum, Lactobacillus delbrueckii and Lactobacillus mucosae to achieve synergistic effects and can repair intestinal damage better and faster.

[0057] In a first aspect, in a specific embodiment of the present application, the present invention provides a composition for improving intestinal infectious damage, which comprises the following components in weight: 30-50 parts of lactic acid bacteria, 20-40 parts of Lactobacillus reuteri postbiotics and 50-120 parts of dietary fiber.

[0058] In some embodiments of the present application, the lactic acid bacteria include Lactobacillus plantarum Ali.Plateau.LP.Ⅷ and Lactobacillus delbrueckii subspecies Dangxiong LBⅧ, wherein the preservation number of Lactobacillus plantarum Ali.Plateau.LP.Ⅷ is CCTCC No.M 2021340, and the preservation number of Lactobacillus delbrueckii subspecies Dangxiong LBⅧ is CCTCC No.M2023396; preferably, the number of viable cells in the lactic acid bacteria is 2.0×10 9 -5.0×10 10 cfu / g.

[0059] In the present application, Lactobacillus plantarum belongs to the genus Lactobacillus in the family Lactobacillaceae. Lactobacillus plantarum has multiple probiotic functions and is one of the members of the "List of Bacteria That Can Be Used to Produce Ordinary Foods" in my country. It is one of the normal intestinal flora and can maintain the pH stability of the intestinal environment, adjust the microbial flora in the gastrointestinal tract, and improve symptoms such as diarrhea, constipation, and indigestion. It is a recognized supplement to human food.

[0060] The Lactobacillus plantarum (Lactiplantibacillus plantarum) Ali.Plateau.LP.VIII of this application is isolated from yak milk in the high-altitude area of ​​Ali, Tibet. It has excellent acid production, acid resistance, antibacterial and antiseptic properties, and animal experiments have shown that Lactobacillus plantarum ALI.Plateau.LP.VIII helps repair intestinal infectious damage. Lactobacillus delbrueckii subsp.Lactis Dangxiong LBVIII has good resistance to gastrointestinal fluid digestion. In addition, Lactobacillus plantarum Ali.Plateau.LP.VIII and Lactobacillus delbrueckii subsp.Lactis Dangxiong LBVIII have a symbiotic effect, and can also have a positive impact on human intestinal health through multiple mechanisms such as regulating intestinal flora and inhibiting pathogenic bacteria infection.

[0061] In some embodiments of the present application, the Lactobacillus reuteri is Limosilactobacillus reuteri NAQU LRV, with the deposit number: CCTCCNO: M20221538.

[0062] The products of the metabolism of Lactobacillus reuteri NAQU LRV of the present application, such as bacteriocins, lactic acid, proteins, and exopolysaccharides, have good antibacterial effects and immunomodulatory functions, thereby effectively protecting intestinal epithelial cells from damage and preventing intestinal infection.

[0063] In some embodiments of the present application, the composition for improving intestinal infectious damage includes the following components by weight: 30-50 parts of lactic acid bacteria, 30-40 parts of Lactobacillus reuteri postbiotics, and 60-85 parts of dietary fiber; preferably, the composition for improving intestinal infectious damage includes the following components by weight: 40-50 parts of lactic acid bacteria, 30-40 parts of Lactobacillus reuteri postbiotics, and 80-85 parts of dietary fiber. Within the above range, the composition has a better effect of improving intestinal infectious damage.

[0064] In some embodiments of the present application, the dietary fiber includes one or more of fructo-oligosaccharides, inulin and xylo-oligosaccharides. Preferably, the dietary fiber includes fructo-oligosaccharides, inulin and xylo-oligosaccharides; more preferably, in parts by weight, the dietary fiber includes 15-50 parts of inulin, 15-50 parts of fructo-oligosaccharides and 15-50 parts of xylo-oligosaccharides, preferably, the dietary fiber includes 15-20 parts of inulin, 30-40 parts of fructo-oligosaccharides and 15-35 parts of xylo-oligosaccharides, more preferably, the dietary fiber includes 15-20 parts of inulin, 35-40 parts of fructo-oligosaccharides and 20-35 parts of xylo-oligosaccharides.

[0065] In some embodiments of the present application, the composition further comprises fruit and vegetable powder, preferably, in parts by weight, the fruit and vegetable powder is 10 to 15 parts; more preferably, the fruit and vegetable powder comprises one or more of blueberry powder, strawberry powder, cranberry powder and carrot powder. Adding fruit and vegetable powder can improve its taste and add flavor.

[0066] In some embodiments of the present application, the lactic acid bacteria powder is a lactic acid bacteria microcapsule powder, wherein the microcapsule powder comprises a core material and a wall material, the core material comprises lactic acid bacteria, and the wall material comprises a gelling agent and a cross-linking agent;

[0067] Preferably, the gelling agent comprises one or more of sodium alginate, arabinoxylan and arabinoxyoligosaccharide, preferably sodium alginate, arabinoxylan and arabinoxyoligosaccharide, more preferably, the weight ratio of sodium alginate, arabinoxylan and arabinoxyoligosaccharide is 1-2:1-4:0.5-1 in parts by weight;

[0068] More preferably, the cross-linking agent comprises calcium chloride and / or calcium lactate.

[0069] Specifically, the lactic acid bacteria microcapsule powder is prepared by the following method.

[0070] The activated plant lactobacillus Ali.Plateau.LP.Ⅷ and Lactobacillus delbrueckii subspecies Dangxiong LBⅧ are inoculated into an MRS broth culture medium at a weight ratio of 1-3:1 and an inoculation amount of 1-5%, and cultured at 35-40°C for 10-20 hours to reach the logarithmic phase; the bacterial sludge is collected by centrifugation, washed with sterile saline, and then suspended in sterile saline, and the obtained bacterial sludge suspension is mixed with a microcapsule wall material and vacuum freeze-dried to obtain lactic acid bacteria microcapsule powder.

[0071] Furthermore, the sodium alginate solution and the arabinoxylan solution are mixed, and then arabinoxylan oligosaccharide is added to make the concentration of 0.1-1wt%. Then the prepared bacterial mud suspension is added to the mixed solution of sodium alginate-arabinoxylan-arabinoxylan oligosaccharide, and laccase (1-2nkat / mg arabinoxylan) is added, and the mixture is added to the CaCl2 solution and allowed to stand for 20-40min to allow the sodium alginate and CaCl2 to react. 2+ The cross-linking reaction between them is fully carried out to finally form calcium alginate-arabinoxylan gel spheres, and then the lactic acid bacteria microcapsule powder is obtained by freeze-drying.

[0072] The lactic acid bacteria microcapsule freeze-dried powder prepared by the present application adopts microcapsule-vacuum freezing technology, and lactic acid bacteria not only reduce the damage of the gastrointestinal environment to the viable bacterial cells by embedding, reduce the loss of viable bacteria count, improve the activity of probiotics in the gastrointestinal tract, but also can realize the efficient release of probiotics in the human intestinal tract, and guarantee the effect of lactic acid bacteria to the greatest extent. In the process of preparing the lactic acid bacteria microcapsule freeze-dried powder, the microcapsule wall material prepared by sodium alginate (natural polysaccharide) and arabinoxylan (prebiotic) is not only natural, safe and stable in composition, but also effectively improves the activity of lactic acid bacteria in the freeze-drying process.

[0073] The present application also provides a method for preparing the above-mentioned composition, which is prepared by stirring and mixing the raw materials; preferably, the dietary fiber and fruit and vegetable powder are stirred and mixed, and then stirred and mixed with the lactic acid bacteria and Lactobacillus reuteri postbiotics; more preferably, the stirring speed is 3-7 r / min, and the preferred stirring time is 15-30 min.

[0074] In some embodiments of the present application, the lactic acid bacteria is lactic acid bacteria microcapsule powder, and the lactic acid bacteria microcapsule powder comprises the following steps:

[0075] (1) fermenting lactic acid bacteria to obtain bacterial sludge, and then preparing a heavy suspension;

[0076] (2) Adding a gelling agent and a cross-linking agent to the resuspension in step (1) to react, and then freeze-drying to obtain lactic acid bacteria microcapsule powder.

[0077] In some embodiments of the present application, the Lactobacillus reuteri postbiotics are prepared by the following steps:

[0078] (1) inoculating the activated Lactobacillus reuteri into a fermentation medium for fermentation;

[0079] (2) heating the fermentation liquid from step (1) to sterilize and inactivate it;

[0080] (3) homogenizing and spray-drying the fermented liquid inactivated in step (2) to obtain Lactobacillus reuteri powder;

[0081] Preferably, the fermentation medium in step (1) comprises 140-160 parts by weight of skim milk powder, 20-40 parts by weight of glucose and 10-30 parts by weight of peptone; and / or,

[0082] Step (2) heating to 60-80°C for sterilization and / or

[0083] The air inlet temperature of the spray drying in step (3) is 130-160°C, and the air outlet temperature is 40-60°C.

[0084] In the above method for preparing postbiotics of Lactobacillus mucilaginosus, step (2) heating and sterilizing includes the step of adding maltodextrin to the fermentation broth. Maltodextrin, as a binder, can improve the quality and stability of the spray-dried powder, as well as improve the taste and texture of the product, and facilitate the subsequent production of postbiotic powder,

[0085] In the present application, Lactobacillus reuteri NAQU LRV postbiotic powder improves the bioavailability of the strain by combining the characteristics of the bacteria itself and its metabolites. The metabolites in the inactivated Lactobacillus reuteri NAQU LRV contain a large number of bioactive molecules, which have great potential in improving human health. Moreover, the probiotic properties of the inactivated Lactobacillus reuteri NAQU LRV and its metabolites do not depend on the activity of probiotics and can better adhere to intestinal mucus, which has higher stability and safety than living microorganisms.

[0086] Specifically, the preparation method of the postbiotic powder comprises the following steps: activating the activated Lactobacillus reuteri NAQU LRV according to 1-5×10 7 CFU / mL is inoculated into 1000mL of sterilized fermentation medium, and fermented at a constant temperature of 35-40℃ to below pH4.5, preferably 3.0-4.5 to terminate the fermentation. After the fermentation is completed, the fermentation liquid is preheated to 60-80℃, and 3%-5% maltodextrin is added and stirred for 10-15min, and zero-pressure homogenization is performed for 10-20min and the colloid is ground. Finally, the fermented milk is spray-dried (inlet air temperature 130-160℃, outlet air temperature 40-60℃) to obtain postbiotic powder.

[0087] In some embodiments of the present application, the fermentation medium comprises the following components in parts by weight: 100-200 parts of skim milk powder, 10-50 parts of glucose, and 10-50 parts of peptone.

[0088] The present application also provides the use of the above composition or the composition prepared by the above preparation method in the preparation of medicines, health products or foods for improving intestinal infectious damage.

[0089] The present application also provides a medicine, health product or food containing the above composition. Preferably, the food is one of a compressed candy or a solid beverage. Compared with medicine, the application is simple to operate and safer.

[0090] In some embodiments of the present application, the above-mentioned medicine, health product or food also includes edible excipients or pharmaceutically acceptable excipients.

[0091] The term "pharmaceutically acceptable excipients" as used herein include any and all pharmaceutically acceptable carriers or diluents, solvents, dispersion media, coatings, surfactants, antioxidants, preservatives, isotonic agents, absorption delaying agents, salts, preservatives, stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc. or any combination thereof, as known to those of ordinary skill in the art. Any excipient known in the art can be used in a pharmaceutical composition or pharmaceutical formulation as long as it is compatible with the active ingredient.

[0092] As used herein, edible excipients refer to edible substances that do not provide health care functions alone. It should be understood that "edible raw materials and excipients" can be selected from substances that are allowed to be added in the health care product management regulations, and further, do not include substances that are prohibited from being added in the health care product management regulations. If not specifically limited, the health care product management regulations refer to the current regulations at the time of production.

[0093] The beneficial effects of the present invention are further illustrated by specific examples below.

[0094] The raw materials and reagents used in the present invention are all purchased from mainstream manufacturers in the market. Those without manufacturer or concentration are all analytically pure raw materials and reagents that can be routinely obtained. As long as they can play the expected role, there is no special limitation.

[0095] If no specific technology or conditions are specified in this embodiment, the process shall be carried out according to the technology or conditions described in the literature in the art or according to the product manual.

[0096] Hereinafter, the present invention will be described in more detail using examples and comparative examples, but the technical scope of the present invention is not limited to these examples. It should be noted that, unless otherwise specified, all percentages, parts, and ratios used in the present invention are based on mass.

[0097] The sources of the reagents and instruments used in the following examples are shown in Table 1.

[0098] Table 1 Raw material information used in the examples

[0099]

[0100] Example 1

[0101] 1. Preparation of lactic acid bacteria microcapsules

[0102] Step 1: Inoculate activated plant lactobacillus Ali.Plateau.LP.Ⅷ and Lactobacillus delbrueckii subspecies Dangxiong LBⅧ into MRS broth medium at a weight ratio of 2:1 and an inoculum size of 2% (by volume), and culture at 37°C for 16h to reach the logarithmic phase; collect bacterial sludge by centrifugation (4°C, 8000r / min, 10min), wash three times with sterile saline (10ml0.9%) to obtain bacterial sludge, and then suspend in 10ml0.9% sterile saline.

[0103] Among them, the formula of MRS broth medium is: glucose 20g / L, peptone 10g / L, beef extract 10g / L, yeast powder 5g / L, sodium acetate 5g / L, diammonium citrate 2g / L, potassium dihydrogen phosphate 2g / L, magnesium sulfate 0.5g / L, manganese sulfate 0.25g / L, Tween 80 1g / L, pH is adjusted to 6.5, and sterilized at 121℃ and 0.1MPa for 15min.

[0104] Step 2: 15 mL of sodium alginate (2 wt%) solution and 15 mL of arabinoxylan solution (2 wt%) were mixed in equal volumes, and then arabinoxylan was added to make its concentration 0.5 wt%. Then 5 mL of the bacterial suspension prepared in step 1 was added to the mixed solution of sodium alginate-arabinoxylan-arabinoxylan, and laccase (1.67 nkat / mg arabinoxylan) was added. After mixing evenly, the mixture was added to 0.1 mol / L sterile CaCl2 solution and allowed to stand for 30 min to allow the sodium alginate and CaCl2 to react. 2+ The cross-linking reaction between them is fully carried out to obtain microcapsules.

[0105] Step 3: The microcapsules prepared in step 3 were subjected to vacuum freeze drying to obtain lactic acid bacteria microcapsule powder. The number of viable bacteria in the lactic acid bacteria microcapsules was measured to be 3.1 x 10 9 CFU / g.

[0106] 2. Preparation of Lactobacillus reuteri postbiotics

[0107] The activated Lactobacillus reuteri NAQU LRV was added at 2x10 7CFU / mL was inoculated into 1000mL of sterilized fermentation medium, and fermented at a constant temperature of 37°C until pH 4.5 was reached to terminate the fermentation. After the fermentation was completed, the fermentation liquid was preheated to 60°C, and 3% maltodextrin was added and stirred for 10 minutes for sterilization and inactivation. Then, zero-pressure homogenization was performed for 10 minutes and the colloid was ground. Finally, the inactivated fermented milk was spray-dried with an inlet air temperature of 150°C and an outlet air temperature of 45°C to obtain postbiotic powder. The fermentation medium consisted of 150g skim milk powder, 30g glucose, 20g peptone and 1000g water.

[0108] 3. Preparation of a composition for improving intestinal infection damage

[0109] 30g of oligofructose, 15g of oligoxylose and 15g of inulin were stirred and mixed (5r / min, 30min) to prepare a composite dietary fiber powder. Then 10g of blueberry powder was added to the composite dietary fiber powder. Finally, 60g of the prepared mixed dietary fiber powder with blueberry flavor was mixed with 30g of lactic acid bacteria microcapsule powder and 30g of postbiotic powder to prepare a composition for improving intestinal infection damage.

[0110] Example 2

[0111] 1. Preparation of lactic acid bacteria microcapsules

[0112] Step 1: activated plant lactobacillus Ali.Plateau.LP.Ⅷ and Lactobacillus delbrueckii lactis subspecies Dangxiong LBⅧ were accessed into MRS broth (MRS broth formula is the same as in Example 1) according to a weight ratio of 1:1 and an inoculum size of 4% (by volume), and cultivated at 37 ℃ for 16 h to reach the logarithmic phase; centrifuged (4 ℃, 8000r / min, 10min) to collect bacterial mud, washed three times with sterile physiological saline (10ml0.9%) to obtain bacterial mud, and then suspended in 10ml0.9% sterile physiological saline.

[0113] Step 2: 15 mL of sodium alginate solution (2 wt%) and 15 mL of arabinoxylan solution (4 wt%) were mixed in equal volumes, and then arabinoxylan was added to make its concentration 0.5 wt%. Then 5 mL of the bacterial suspension prepared in step 1 was added to the mixed solution of sodium alginate-arabinoxylan-arabinoxylan, and laccase (2 nkat / mg arabinoxylan) was added. After mixing evenly, the mixture was added to 0.1 mol / L sterile CaCl2 solution and allowed to stand for 30 min to allow the sodium alginate and CaCl2 to react. 2+ The cross-linking reaction between them is fully carried out to obtain microcapsules.

[0114] Step 3: The microcapsules prepared in step 3 were subjected to vacuum freeze drying to obtain lactic acid bacteria microcapsule powder. The number of viable bacteria in the lactic acid bacteria microcapsules was measured to be 3.2 x 10 9 CFU / g.

[0115] 2. Preparation of Lactobacillus reuteri postbiotics

[0116] The activated Lactobacillus reuteri NAQU LR was added at 5x10 7 CFU / mL was inoculated into 1000mL of sterilized fermentation medium, and fermented at a constant temperature of 37°C until pH 3.0 was reached to terminate the fermentation. After the fermentation was completed, the fermentation liquid was preheated to 60°C, and 5% maltodextrin was added and stirred for 10 minutes for sterilization and inactivation. Then, zero-pressure homogenization was performed for 10 minutes and the colloid was ground. Finally, the inactivated fermented milk was spray-dried with an inlet air temperature of 160°C and an outlet air temperature of 60°C to obtain postbiotic powder. The fermentation medium consisted of 100g skim milk powder, 50g glucose, 50g peptone and 1000g water.

[0117] 35g of oligofructose, 35g of oligoxylose and 15g of inulin were stirred and mixed (5r / min, 30min) according to the mass ratio to obtain a composite dietary fiber powder. Then 15g of carrot powder was added to the composite dietary fiber powder. Finally, 100g of the obtained mixed dietary fiber powder with carrot flavor was mixed with 40g of lactic acid bacteria microcapsule powder obtained in step 1 and 40g of postbiotic powder obtained in step 2 to prepare a composition for improving intestinal infection damage.

[0118] Example 3

[0119] Preparation of composition for improving intestinal infection damage

[0120] 40g of oligofructose, 20g of oligoxylose and 20g of inulin were stirred and mixed (5r / min, 30min) according to the mass ratio to prepare a composite dietary fiber powder. Then 10g of strawberry powder was added to the composite dietary fiber powder. Finally, 90g of the prepared mixed dietary fiber powder with strawberry flavor was mixed with 50g of lactic acid bacteria microcapsule powder prepared in Example 1 and 40g of postbiotic powder prepared in Example 1 to prepare a composition for improving intestinal infection damage.

[0121] Example 4

[0122] Preparation of composition for improving intestinal infection damage

[0123] 50g of oligofructose, 50g of oligoxylose and 15g of inulin were stirred and mixed (5r / min, 30min) according to the mass ratio to obtain a composite dietary fiber powder. Then 10g of strawberry powder was added to the composite dietary fiber powder. Finally, 125g of the obtained mixed dietary fiber powder with strawberry flavor was mixed with 30g of lactic acid bacteria microcapsule powder obtained in Example 1 and 20g of postbiotic powder obtained in Example 1 to prepare a composition for improving intestinal infection damage.

[0124] Example 5

[0125] Preparation of composition for improving intestinal infection damage

[0126] 15g of oligofructose, 45g of oligoxylose and 50g of inulin were stirred and mixed (5r / min, 30min) according to the mass ratio to obtain a composite dietary fiber powder. Then 15g of strawberry powder was added to the composite dietary fiber powder. Finally, 125g of the obtained mixed dietary fiber powder with strawberry flavor was mixed with 40g of lactic acid bacteria microcapsule powder obtained in Example 1 and 50g of postbiotic powder obtained in Example 1 to prepare a composition for improving intestinal infection damage.

[0127] Comparative Example 1

[0128] Preparation of composition for improving intestinal infection damage

[0129] 10 g of strawberry powder was mixed with 50 g of the lactic acid bacteria microcapsule powder obtained in Example 1 and 120 g of maltodextrin to prepare a composition for improving intestinal infection damage.

[0130] Comparative Example 2

[0131] Preparation of composition for improving intestinal infection damage

[0132] 10 g of strawberry powder was mixed with 40 g of the postbiotic powder prepared in Example 1 and 130 g of maltodextrin to prepare a composition for improving intestinal infection damage.

[0133] Comparative Example 3

[0134] Preparation of composition for improving intestinal infection damage

[0135] 40g of oligofructose, 20g of oligoxylose and 20g of inulin were stirred and mixed (5r / min, 30min) to prepare a composite dietary fiber powder. Then 10g of strawberry powder was added to the composite dietary fiber powder. Finally, 90g of the prepared mixed dietary fiber powder with strawberry flavor and 90g of maltodextrin were used to prepare a composition for improving intestinal infection damage.

[0136] Comparative Example 4

[0137] Preparation of composition for improving intestinal infection damage

[0138] 40g of oligofructose, 20g of oligoxylose and 20g of inulin were stirred and mixed (5r / min, 30min) according to the mass ratio to obtain a composite dietary fiber powder. Then 10g of strawberry powder was added to the composite dietary fiber powder. Finally, 90g of the obtained mixed dietary fiber powder with strawberry flavor was mixed with 50g of lactic acid bacteria microcapsule powder obtained in Example 1 and 40g of maltodextrin to prepare a composition for improving intestinal infection damage.

[0139] Comparative Example 5

[0140] Preparation of composition for improving intestinal infection damage

[0141] 40g of oligofructose, 20g of oligoxylose and 20g of inulin were stirred and mixed (5r / min, 30min) according to the mass ratio to obtain a composite dietary fiber powder. Then 10g of strawberry powder was added to the composite dietary fiber powder. Finally, 90g of the obtained mixed dietary fiber powder with strawberry flavor was mixed with 50g of maltodextrin and 40g of the postbiotic powder obtained in Example 1 to prepare a composition for improving intestinal infection damage.

[0142] Experimental Example 1 Composition for Improving Intestinal Infection Damage - Animal Experiment on Escherichia coli

[0143] 1. Experimental Animals

[0144] One hundred and twenty healthy male mice aged 6-8 weeks were selected. The mice were raised under natural light, with a temperature of (24±1)°C and a relative humidity of (30±3)%. The bedding was replaced and the cages were cleaned in time.

[0145] 2. Experimental Methods

[0146] The mice were randomly divided into 12 treatment groups, including comparison group 1, comparison group 2, comparison group 3, comparison group 4, comparison group 5, example group 1, example group 2, example group 3, example group 4, example group 5, normal group (not infected with Escherichia coli), and infection group (infected with Escherichia coli), with 10 mice in each group.

[0147] Inoculation of mice with E. coli: Except for the normal group, all other groups were inoculated with E. coli. Each mouse was orally fed with 0.2 mL (concentration 2*10 10 The normal group and the infection group were fed with conventional feed, and the other groups were fed with the corresponding composition for improving intestinal infection damage. The specific grouping and feeding operation are shown in Table 2.

[0148] After 3 days of feeding, the mice were dissected and the mouse intestines were quickly separated. The collected mouse intestinal tissues were fixed in 4% paraformaldehyde solution for storage and preparation of tissue sections. HE staining was used and the mouse intestinal tissue morphology (including villus length VL, crypt depth CD and V / C value) was used as the measurement index. The results are shown in Table 3.

[0149] Table 2 Experimental groups and operations

[0150]

[0151]

[0152] The effects of different compositions on intestinal injury mice are shown in Table 3.

[0153] Table 3 Results of determination of villus length (VL), crypt depth (CD) and V / C in mouse intestine

[0154]

[0155]

[0156] The experimental results showed that the villus length (VL) of mice in Example 3 group was significantly higher than that in the infection group (P<0.01), and significantly higher than that in Comparative Examples 1-5 (P<0.05). Comparative Example 4 group was higher than that in Comparative Example 1 group (P<0.05), and Comparative Example 5 group was higher than that in Comparative Example 2 group (P<0.05). In addition, the villus length of Example 3 group was slightly higher than that of the normal group.

[0157] The CD value of mice in the normal group was significantly lower than that of the infected group and the control groups 1-5 (P<0.05), but the difference was not significant compared with the group in Example 3 (P>0.05). The CD value of the control group 4 was lower than that of the control group 1 (P<0.05), and the value of the control group 5 was lower than that of the control group 2 (P<0.05).

[0158] By calculating the V / C value of each group of mice, it was found that the CD value of the normal group of mice was significantly higher than that of the infected group and the comparative example 1-5 groups (P<0.05), but the difference was not significant compared with the Example 3 group (P>0.05). The CD value of the comparative example 4 group was higher than that of the comparative example 1 group (P<0.05), and the value of the comparative example 5 group was higher than that of the comparative example 2 group (P<0.05).

[0159] From the V / C ratio, it can be seen that compared with the infection group, the V / C ratios of Examples 1-5 increased by 35.8-53.7%, among which the V / C ratio of Example 3 increased by 53.7%, the V / C value of Comparative Example 1 increased by 21.4%, the V / C value of Comparative Example 2 increased by 21.4%, the V / C value of Comparative Example 3 increased by 5.2%, the V / C value of Comparative Example 4 increased by 26.6%, and the V / C value of Comparative Example 5 increased by 23.1%. Therefore, in the composition for intestinal infection damage covered by the present application, there is a certain degree of synergy between lactic acid bacteria and postbiotics and dietary fiber, between postbiotics and lactic acid bacteria and dietary fiber, and between lactic acid bacteria, postbiotics and dietary fiber for repairing intestinal damage.

[0160] Experimental Example 2 Preventive and therapeutic effects of the composition for improving intestinal infection damage on pathogenic bacteria infection 1. Escherichia coli infection model

[0161] 1. Experimental Animals

[0162] Fifty healthy male mice aged 6-8 weeks were selected. The mice were raised under natural light, with a temperature of (24±1)°C and a relative humidity of (30±3)%. The bedding was replaced and the cages were cleaned in time.

[0163] 2. Experimental Methods

[0164] The mice were randomly divided into a blank group, Example 3 group, Escherichia coli group, Example 3 group + Escherichia coli group and Example 3 group mixed with Escherichia coli group, a total of 5 treatment groups, with 10 mice in each group.

[0165] The operations of each treatment group are shown in Table 4.

[0166] The grouping and operations are shown in Table 4.

[0167] Table 4 Experimental groups and operations of E. coli infection model

[0168]

[0169] 2. Salmonella Typhimurium Infection Model

[0170] 1. Experimental Animals

[0171] Fifty healthy male mice aged 6-8 weeks were selected. The mice were raised under natural light, with a temperature of (24±1)°C and a relative humidity of (30±3)%. The bedding was replaced and the cages were cleaned in time.

[0172] 2. Experimental Methods

[0173] The mice were randomly divided into a blank group, Example 3 group, rat Salmonella group, Example 3 group + rat Salmonella group and Example 3 group mixed with rat Salmonella group, a total of 5 treatment groups, with 10 mice in each group.

[0174] The operations of each treatment group are shown in Table 5.

[0175] The grouping and operations are shown in Table 5.

[0176] Table 5 Experimental groups and procedures of the Salmonella typhimurium infection model

[0177]

[0178] The pathogenic bacteria infected model mice were intervened and treated with the composition for improving intestinal infection damage in Example 3, and the protective effect of the composition on infectious intestinal damage was evaluated by the intestinal barrier and intestinal structural integrity. When evaluating the protective effect of the composition, the preventive intervention and then infection (i.e., the composition for improving intestinal infection damage was given preventively, and then the infection model was established, which was recorded as Example 3 Group + Escherichia coli Group and Example 3 Group + Salmonella Group in this study) and real-time treatment of infection (i.e., the composition for improving intestinal infection damage was taken at the same time of infection, which was recorded as Example 3 Group mixed with Escherichia coli Group and Example 3 Group mixed with Salmonella Group) were used. During the period, the weight and clinical manifestations of the mice were recorded. After the feeding experiment, the animals were killed and the duodenum, jejunum, ileum and colon of each group of mice were collected for HE staining to evaluate the effect of the composition on intestinal tissue structure. The Western blot method (protein immunoblotting) was used to detect the changes in the expression levels of tight junction proteins Zo-1 and Claudin-1 in mouse intestinal cells.

[0179] Among them, the effect of the composition for improving intestinal infectious damage on the intestinal morphology of mice with intestinal damage, such as Figure 1-4 As shown, Figure 1 The results of the experimental study on the repair of the small intestine of mice damaged by E. coli infection by the composition; Figure 2 The results of the experiment on the repair of the small intestine of mice damaged by Salmonella typhimurium infection by the composition; Figure 3 The results of the experiment on the composition repairing the large intestine of mice damaged by E. coli infection; Figure 4 The results are experimental results of the composition repairing the large intestine of mice damaged by Salmonella typhimurium infection.

[0180] Depend on Figure 1 It can be seen that in the E. coli infection model experiment, compared with the normal group, the height of the small intestinal villi in Example 3 group increased, and there was no obvious change in the crypt depth and mucosal thickness; compared with the normal group, the height of the small intestinal villi in the E. coli group decreased, the mucosal thickness became thinner, the crypt thickness did not change significantly, and there was edema at the tip of the villi; the height of the small intestinal villi and the mucosal thickness of the Example 3 group + E. coli group and the Example 3 group mixed with E. coli group were greater than those of the E. coli group, and the villus edema phenomenon was significantly improved.

[0181] Depend on Figure 2 It can be seen that in the experiment of Salmonella typhimurium infection model, compared with the normal group, the height of the small intestinal villi in the Example 3 group increased, and the crypt depth and mucosal thickness did not change significantly; compared with the normal group, the height of the small intestinal villi in the Salmonella typhimurium group decreased, the mucosal thickness and crypt thickness did not change significantly, and there was edema at the tip of the villi; the height of the small intestinal villi in the Example 3 group + Salmonella typhimurium group and the Example 3 group mixed with Salmonella typhimurium group were greater than those in the Salmonella typhimurium group, and the villus edema phenomenon improved.

[0182] Depend on Figure 3 It can be seen that in the E. coli infection model experiment, compared with the normal group, the height of the large intestinal villi in the Example 3 group increased, and the crypt depth and mucosal thickness did not show obvious changes; compared with the normal group, the E. coli group had a reduced height of the large intestinal villi, a thinner mucosal thickness, no obvious change in crypt thickness, and edema at the tip of the villi; the height of the large intestinal villi and mucosal thickness of the Example 3 group + E. coli group and the probiotics mixed E. coli group were greater than those of the E. coli group, and the villus edema phenomenon improved; the improvement effect of the Example 3 group mixed E. coli group was slightly lower than that of the Example 3 group + E. coli group.

[0183] Depend on Figure 4 It can be seen that in the experiment of Salmonella typhimurium infection model, compared with the normal group, the height of the large intestinal villi in the Example 3 group increased, and the crypt depth and mucosal thickness did not change significantly; compared with the normal group, the mouse Salmonella group had a reduced height of the large intestinal villi, and the changes in the mucosal thickness and crypt thickness were not obvious, and there was edema at the tip of the villi; the height of the large intestinal villi and the mucosal thickness of the Example 3 group + the mouse Salmonella group and the Example 3 group mixed with the mouse Salmonella group were greater than the mouse Salmonella group, and the villus edema phenomenon improved; the improvement effect of the Example 3 group mixed with the mouse Salmonella group was slightly lower than that of the Example 3 group + the mouse Salmonella group.

[0184] The protein immunoblotting method was used to determine the expression levels of the target proteins Claudin-1 and Zo-1 in the intestinal tissues. GAPDH was used as the internal reference protein. The target proteins were separated by SDS-PAGE gel, and the corresponding antibodies and colorants were used to complete the color development of the target proteins. The protein expression was semi-quantified by its chromaticity (i.e., gray value). This method was used to indirectly evaluate the promoting effect of the composition on barrier repair after intestinal damage.

[0185] Western blotting results Figure 5-7 As shown, Figure 5 The expression of Claudin-1 in small intestine tissue in the E. coli infection model; Figure 6 The expression of Claudin-1 in the small intestine in the Salmonella typhimurium infection model; Figure 7 Expression of Zo-1 in the small intestine of infection model mice.

[0186] Depend on Figure 5-6 It can be seen that the experimental results show that in the E. coli infection model experiment, compared with the blank group, the expression of Claudin-1 protein in the Example 3 group has an increasing trend; compared with the E. coli group, the preventive intervention of the composition for improving intestinal infectious damage can correct the decrease of Claudin-1 caused by E. coli infection. However, no obvious changes were observed in the mouse Salmonella infection.

[0187] Depend on Figure 7 It can be seen that compared with the blank group, the expression of Zo-1 protein in Example 3 group tends to increase; compared with the intestinal damage groups (including the Escherichia coli group and the Salmonella enterica serovar group), the preventive treatment of Example 3 group can significantly correct the expression of Zo-1 protein caused by Escherichia coli and Salmonella infection.

[0188] In summary, the Example 3 group was able to reverse the effects of pathogenic bacteria Escherichia coli and Salmonella typhimurium on the intestinal villus structure to a certain extent, and preventive intervention with the composition of Example 3 could protect the integrity of the intestinal epithelial barrier to a certain extent.

[0189] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A composition for improving intestinal infectious damage, characterized in that: The invention comprises the following components in parts by weight: 30-50 parts of lactic acid bacteria, 20-50 parts of Lactobacillus reuteri postbiotics and 50-120 parts of dietary fiber.

2. The composition according to claim 1, characterized in that The lactic acid bacteria include Lactobacillus plantarum Ali.Plateau.LP.VIII and Lactobacillus delbrueckii subsp.Lactis Dangxiong LBVIII, wherein the preservation number of the Lactobacillus plantarum Ali.Plateau.LP.VIII is CCTCC No.M 2021340, and the preservation number of the Lactobacillus delbrueckii subsp.Lactis Dangxiong LBVIII is CCTCC No.M 2023396; Preferably, the number of viable bacteria in the lactic acid bacteria is 2.0×10 9 -5.0×10 10 CFU / g.

3. The composition according to claim 1 or 2, characterized in that The Lactobacillus reuteri is Limosilactobacillus reuteri NAQU LR V, and its deposit number is CCTCC NO: M20221538.

4. The composition according to any one of claims 1 to 3, characterized in that The invention comprises the following components by weight: 30-50 parts of lactic acid bacteria, 30-40 parts of Lactobacillus reuteri postbiotics and 60-85 parts of dietary fiber; Preferably, the composition comprises the following components in parts by weight: 40-50 parts of lactic acid bacteria, 30-40 parts of Lactobacillus reuteri postbiotics and 80-85 parts of dietary fiber.

5. The composition according to any one of claims 1 to 4, characterized in that The dietary fiber includes one or more of oligofructose, inulin and oligoxylose; Preferably, the dietary fiber includes fructooligosaccharides, inulin and xylo-oligosaccharides; More preferably, in parts by weight, the dietary fiber comprises 15-50 parts of inulin, 15-50 parts of fructo-oligosaccharides and 15-50 parts of xylo-oligosaccharides; preferably, the dietary fiber comprises 15-20 parts of inulin, 30-40 parts of fructo-oligosaccharides and 15-35 parts of xylo-oligosaccharides; more preferably, the dietary fiber comprises 15-20 parts of inulin, 35-40 parts of fructo-oligosaccharides and 20-35 parts of xylo-oligosaccharides.

6. The composition according to any one of claims 1 to 5, characterized in that The composition also includes fruit and vegetable powder; Preferably, the fruit and vegetable powder is 10 to 15 parts by weight; More preferably, the fruit and vegetable powder includes one or more of blueberry powder, strawberry powder, cranberry powder and carrot powder.

7. The composition according to any one of claims 1 to 6, characterized in that The lactic acid bacteria powder is lactic acid bacteria microcapsule powder, wherein the microcapsule powder comprises a core material and a wall material, the core material comprises lactic acid bacteria, and preferably the wall material comprises a gelling agent, a cross-linking agent and laccase; Preferably, the gelling agent comprises one or more of sodium alginate, arabinoxylan and arabinoxy-oligosaccharide, preferably sodium alginate, arabinoxylan and arabinoxy-oligosaccharide, more preferably, the weight ratio of sodium alginate, arabinoxylan and arabinoxy-oligosaccharide is 1-2:1-4:0.5-1, and further preferably, the addition amount of the laccase is 1-2nkat / mg arabinoxylan; More preferably, the cross-linking agent comprises calcium chloride and / or calcium lactate.

8. The composition according to any one of claims 1 to 7, characterized in that The Lactobacillus reuteri postbiotic is prepared by fermenting and inactivating Lactobacillus reuteri and then spray-drying the fermented Lactobacillus reuteri.

9. A method for preparing the composition according to any one of claims 1 to 8, characterized in that: Stir and mix all the raw materials; Preferably, the dietary fiber and the fruit and vegetable powder are stirred and mixed, and then stirred and mixed with the lactic acid bacteria and the Lactobacillus reuteri postbiotics. More preferably, the stirring speed is 3-7 r / min, and the preferred stirring time is 15-30 min.

10. The preparation method according to claim 9, characterized in that: The lactic acid bacteria is lactic acid bacteria microcapsule powder, and the lactic acid bacteria microcapsule powder comprises the following steps: (1) fermenting lactic acid bacteria to obtain bacterial sludge, and then preparing a heavy suspension; (2) Adding a gelling agent, laccase and a cross-linking agent to the resuspended solution of step (1) to react, and then freeze-drying to obtain lactic acid bacteria microcapsule powder.

11. The preparation method according to claim 9 or 10, characterized in that: The Lactobacillus reuteri postbiotics are prepared by the following steps: (1) inoculating the activated Lactobacillus reuteri into a fermentation medium for fermentation; (2) heating the fermentation liquid from step (1) to sterilize and inactivate it; (3) homogenizing the fermentation liquid inactivated in step (2), and then spray drying to obtain Lactobacillus reuteri powder; Preferably, the fermentation medium in step (1) comprises 140-160 parts by weight of skim milk powder, 20-40 parts by weight of glucose and 10-30 parts by weight of peptone; and / or, Step (2) heating to 60-80°C for sterilization and / or The air inlet temperature of the spray drying in step (3) is 130-160°C, and the air outlet temperature is 40-60°C.

12. Use of the composition according to any one of claims 1 to 8 or the composition prepared by the preparation method according to any one of claims 9 to 11 in the preparation of drugs, health products or foods for improving intestinal infectious damage.

13. A medicine, health product or food containing the composition according to claims 1-8 or the composition prepared by the preparation method according to any one of claims 9-11; preferably, the food is one of a compressed candy or a solid beverage.

14. The medicine, health product or food according to claim 13, characterized in that: It also includes auxiliary materials; preferably, the auxiliary materials are selected from one or more of sucrose, mannitol, sorbitol, dextrin, magnesium stearate, lactose, microcrystalline cellulose, starch, white sugar, xylose and sucralose steviol glycoside.

Images